

HEXIMA LIMITED

ASX ANNOUNCEMENT



2 December 2021

SHARI LIPNER APPOINTED TO SAB

Highly Influential, US-based Dermatologist

MELBOURNE, AUSTRALIA (2 December 2021): Hexima Limited (ASX:HXL) a clinical stage biotechnology company developing pezadeftide (formerly HXP124), as a potential new prescription topical treatment for onychomycosis, today announces the appointment of Shari Lipner, MD as a member of Hexima's Scientific Advisory Board. Dr Lipner joins a high-profile advisory board comprising dermatologists and podiatrists based in Australia, the US and Japan.

Dr. Lipner is an Associate Professor of Clinical Dermatology, Associate Attending Physician, and Director of the Nail Division at the New York-Presbyterian Hospital/Weill Cornell Medical Center. Dr. Lipner has authored over two-hundred and fifty peer-reviewed publications, numerous book chapters, lectures nationally and internationally, and is a frequently sought out by the media for her expertise. She completed her undergraduate studies at Dartmouth College where she obtained a Bachelor of Arts in Chemistry and graduated Phi Beta Kappa and Summa Cum Laude. Dr. Lipner completed her medical training at Albert Einstein College of Medicine, where she received both M.D. and Ph.D degrees and graduated Alpha Omega Alpha. She completed her residency training in Dermatology at the New York-Presbyterian Hospital/Weill Cornell Medical Center.

Michael Aldridge, Managing Director & CEO said, "We have been very pleased with the calibre of international Key Opinion Leaders we have assembled to assist and advise Hexima in this exciting and critical stage of clinical development.

"We have attracted expertise in Australia and in the large global markets of the US and Japan. The leading voices in the dermatology and podiatric community are important advocates for our goal of bringing pezadeftide to patients as a new, safe and effective treatment for onychomycosis."

This announcement is authorised for release to ASX by Michael Aldridge, Managing Director & CEO

Enquiries:

Dr Nicole van der Weerden
Chief Operating Officer
n.vanderweerden@hexima.com.au

To join our email database and receive company announcements please [click here](#)

ABOUT HEXIMA

Hexima (ASX:HXL) is a clinical stage, anti-infectives focused biotechnology company engaged in the research and development of defensin peptides for applications as human therapeutics. Our lead product candidate, pezadeftide (HXP124) applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting an Australian phase IIb clinical trial testing pezadeftide for the treatment of onychomycosis. Hexima holds granted, long-life patents protecting pezadeftide in major markets globally. For additional information please visit www.hexima.com.au. You can also find us on [Twitter](#) and [LinkedIn](#) or email us at info@hexima.com.au.